Versant Ventures

Granite Bio is a biotechnology company focused on developing novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company specializes in creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological processes associated with these diseases. By concentrating on these advanced treatments, Granite Bio contributes to the broader fields of biotechnology, pharmaceuticals, and diagnostics, ultimately seeking to improve patient outcomes in complex medical conditions.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based medicines specifically for kidney diseases. The company utilizes its expertise in molecular and cellular biology, chemistry, and analytical capabilities to identify target opportunities within different patient subsets affected by kidney conditions. By refining methods for delivering RNA medicines to specific cell types, Borealis Biosciences aims to tackle significant unmet medical needs in the treatment of kidney diseases.

ViaLase is a medical technology company based in Corona Del Mar, California, that specializes in developing an innovative image-guided femtosecond laser surgical system for treating open-angle glaucoma. Founded in 2019, the company utilizes micron-resolution optical coherence tomography (OCT) to guide its laser technology in creating precise, micron-sized drainage channels through the trabecular meshwork. This approach connects the anterior chamber to Schlemm's canal without the need for surgical incisions or penetration of the eye, thereby offering a non-invasive treatment option for glaucoma management. By enhancing the efficiency of glaucoma procedures, ViaLase aims to improve patient outcomes in this challenging area of ophthalmic care.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Inari Medical, Inc. is a commercial-stage medical device company headquartered in Irvine, California, that specializes in developing innovative products for patients with venous diseases. Founded in 2011, the company focuses on treating venous thromboembolism through its advanced catheter-based mechanical thrombectomy devices. The ClotTriever system is designed for the safe and effective removal of large blood clots from peripheral blood vessels, specifically targeting deep vein thrombosis. The FlowTriever system addresses pulmonary embolism by removing clots from the pulmonary arteries. Both devices are FDA-cleared and aim to improve the quality of life for patients by eliminating the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States, while also engaging in international markets.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.

Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Inari Medical, Inc. is a commercial-stage medical device company headquartered in Irvine, California, that specializes in developing innovative products for patients with venous diseases. Founded in 2011, the company focuses on treating venous thromboembolism through its advanced catheter-based mechanical thrombectomy devices. The ClotTriever system is designed for the safe and effective removal of large blood clots from peripheral blood vessels, specifically targeting deep vein thrombosis. The FlowTriever system addresses pulmonary embolism by removing clots from the pulmonary arteries. Both devices are FDA-cleared and aim to improve the quality of life for patients by eliminating the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States, while also engaging in international markets.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Ceterix Orthopaedics, Inc. is a medical technology company focused on developing innovative surgical tools for arthroscopic procedures. Based in Fremont, California, the company offers the Ceterix NovoStitch® Plus Meniscal Repair System, designed to repair various complex meniscal tears, including horizontal, radial, and root tears. Additionally, Ceterix provides the Novocut Suture Manager, a device that facilitates suture management during surgeries. The company's technology allows orthopedic surgeons to non-invasively create intricate suture patterns in tight joint compartments while safeguarding surrounding structures such as nerves and cartilage. Founded in 2010 by Dr. Justin Saliman, an orthopedic surgeon specializing in sports medicine, Ceterix aims to enhance the outcomes of arthroscopic procedures, addressing issues that often lead to untreated tears or the more invasive meniscectomy. As of January 2019, Ceterix operates as a subsidiary of Smith & Nephew plc.

Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Inari Medical, Inc. is a commercial-stage medical device company headquartered in Irvine, California, that specializes in developing innovative products for patients with venous diseases. Founded in 2011, the company focuses on treating venous thromboembolism through its advanced catheter-based mechanical thrombectomy devices. The ClotTriever system is designed for the safe and effective removal of large blood clots from peripheral blood vessels, specifically targeting deep vein thrombosis. The FlowTriever system addresses pulmonary embolism by removing clots from the pulmonary arteries. Both devices are FDA-cleared and aim to improve the quality of life for patients by eliminating the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States, while also engaging in international markets.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company offers ZILRETTA, an intra-articular injection designed to manage knee pain associated with osteoarthritis in the United States. Additionally, Flexion is developing FX201, a gene therapy aimed at stimulating the production of an anti-inflammatory protein to provide pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Founded in 2007, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates through clinical proof of concept and beyond, thereby enhancing their partners' portfolios while sharing expertise and risk.

Cerephex Corporation develops non-invasive treatment and diagnostic technologies for chronic centralized pain conditions, specifically focusing on fibromyalgia. The company's flagship product, NeuroPoint, is a point-of-care medical device utilizing proprietary RINCE technology, which employs noninvasive cortical electrostimulation to target and modulate brain function. This device aims to address the abnormal pain processing mechanisms associated with fibromyalgia. Cerephex is actively working towards obtaining FDA approval for NeuroPoint, enabling its use in clinical outpatient settings under physician supervision. Founded in 2012 and based in Los Altos, California, Cerephex was previously known as Great Lakes BioSciences.

Cotera, Inc. specializes in the design and development of orthopedic implants aimed at treating knee osteoarthritis. Founded in 2011 and located in Menlo Park, California, the company has introduced innovative devices, including the Latella device, which is surgically attached to the femur to alleviate medial knee pain associated with osteoarthritis. This implant not only provides immediate relief but is also designed for easy removal, preserving future treatment options for patients. Cotera's focus is on improving the quality of life for individuals suffering from joint pain through advanced orthopedic solutions.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Zyga Technology, Inc. is a medical device company focused on developing and commercializing minimally invasive products for underserved conditions of the lumbar spine. The company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion, addressing issues such as joint disruptions and degenerative sacroiliitis. Additionally, Zyga is working on the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology has assembled a skilled team with extensive experience in the spine industry. As of late 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Realeve develops miniaturized neurostimulation devices designed to set a new standard in treating severe headache. It focuses on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company was founded in 2007 and is headquartered in Mountain View, California.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company offers ZILRETTA, an intra-articular injection designed to manage knee pain associated with osteoarthritis in the United States. Additionally, Flexion is developing FX201, a gene therapy aimed at stimulating the production of an anti-inflammatory protein to provide pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Founded in 2007, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates through clinical proof of concept and beyond, thereby enhancing their partners' portfolios while sharing expertise and risk.

Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC.

Realeve develops miniaturized neurostimulation devices designed to set a new standard in treating severe headache. It focuses on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company was founded in 2007 and is headquartered in Mountain View, California.

Inogen is a medical technology company that specializes in the development and manufacturing of portable oxygen concentrators for patients with chronic respiratory conditions. Its flagship product, the Inogen One system, offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen markets its products to home medical equipment providers and directly rents them to patients. The company also operates internationally, distributing its products through large gas companies and home oxygen providers. While it serves a global market, the majority of its revenue is generated in the United States. Inogen is committed to enhancing the freedom and independence of oxygen therapy patients through innovative products and superior service.

NovaLign Orthopaedics formerly known as OsteoLign is an orthopaedic medical device company based in Memphis, Tenn. NovaLign recently received its first 510(k) clearance from the FDA to market its new Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur.

LensX Lasers is a developer of surgical lasers used for the reparation of cataracts.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.

Cellutions is developing proprietary medical devices and procedures to treat cellulite, a condition that affects 90% of post-adolescent females. The company is developing a proprietary technology/procedure to be performed in an outpatient setting as a minimally invasive ‘lunchtime' treatment.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis. Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

Microfabrica Inc. designs and develops micro-scale additive manufacturing solutions, focusing on creating complex, micron-precision metal structures through its patented EFAB micro-fabrication technology. Founded in 1999 and headquartered in Van Nuys, California, the company specializes in producing minuscule surgical instruments, including biopsy forceps and tissue scaffolds that expand with cell growth. Its advanced manufacturing process enables the production of fully assembled micro-devices for industries such as aerospace, electronics, and medical devices, allowing customers to achieve significant improvements in functionality, performance, and cost-effectiveness. Microfabrica operates as a subsidiary of Technoprobe S.p.A. and has a secondary office in Santa Clara, California. The company has garnered support from various reputable venture capital and private investors.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Inogen is a medical technology company that specializes in the development and manufacturing of portable oxygen concentrators for patients with chronic respiratory conditions. Its flagship product, the Inogen One system, offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen markets its products to home medical equipment providers and directly rents them to patients. The company also operates internationally, distributing its products through large gas companies and home oxygen providers. While it serves a global market, the majority of its revenue is generated in the United States. Inogen is committed to enhancing the freedom and independence of oxygen therapy patients through innovative products and superior service.

Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections. Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team consists of nine individuals who collectively have been involved in the development and approval of a significant number of anti-infective drugs.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Calypso Medical Technologies is a Seattle-based, privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

Intersection Medical, Inc. is a company focused on the development and marketing of non-invasive medical devices aimed at assisting physicians in the treatment of patients with heart failure. Founded in 2006 and headquartered in Carlsbad, California, the company is also working on innovative technologies designed to enhance visibility into patient health status. These advancements aim to deliver actionable data for both patients and healthcare providers, ultimately improving the management of heart conditions.

Neurotech is a privately held biotechnology company focused on developing innovative therapies for chronic retinal diseases, addressing significant unmet medical needs in the ophthalmology market. The company has created a novel ocular implant that facilitates the continuous production of therapeutic proteins directly in the eye. This system is designed to help therapeutic cells survive in challenging conditions, thereby replacing or supporting the function of deteriorating target cells or tissues. By enhancing the treatment options available for eye diseases, Neurotech aims to improve the quality of life for patients suffering from these conditions.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

ImpediMed Limited is a medical software technology company based in Pinkenba, Australia, that specializes in developing, manufacturing, and selling bioimpedance spectroscopy (BIS) devices and software services globally, with a significant focus on North America. The company offers a range of noninvasive devices, including SOZO, which is designed for detecting lymphedema and monitoring fluid status in heart failure patients. Additionally, ImpediMed provides the SFB7 device for body composition analysis in healthy individuals and ImpediVET for veterinary applications. The company's products are utilized in hospitals and clinics to assess and monitor various health conditions. ImpediMed also features a cloud-based digital platform for managing patient data. Established in 1999, the company continues to innovate in the medical device sector, addressing needs in both human and veterinary healthcare.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Insulet Corporation is a medical device company dedicated to improving the lives of individuals with insulin-dependent diabetes through its innovative Omnipod System. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet develops, manufactures, and markets an insulin delivery system that includes a tubeless, disposable insulin infusion device and a handheld personal diabetes manager. The Omnipod System is designed for ease of use, allowing for automated cannula insertion and smartphone control for dosage management. Insulet primarily sells its products through independent distributors, pharmacy channels, and directly to patients in the United States, Canada, Europe, and the Middle East. Since receiving FDA approval in 2005, the Omnipod System has been adopted by approximately 425,000 insulin-dependent diabetics worldwide, reflecting the company's commitment to enhancing diabetes management.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

Calypso Medical Technologies is a Seattle-based, privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

Inogen is a medical technology company that specializes in the development and manufacturing of portable oxygen concentrators for patients with chronic respiratory conditions. Its flagship product, the Inogen One system, offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen markets its products to home medical equipment providers and directly rents them to patients. The company also operates internationally, distributing its products through large gas companies and home oxygen providers. While it serves a global market, the majority of its revenue is generated in the United States. Inogen is committed to enhancing the freedom and independence of oxygen therapy patients through innovative products and superior service.

Insulet Corporation is a medical device company dedicated to improving the lives of individuals with insulin-dependent diabetes through its innovative Omnipod System. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet develops, manufactures, and markets an insulin delivery system that includes a tubeless, disposable insulin infusion device and a handheld personal diabetes manager. The Omnipod System is designed for ease of use, allowing for automated cannula insertion and smartphone control for dosage management. Insulet primarily sells its products through independent distributors, pharmacy channels, and directly to patients in the United States, Canada, Europe, and the Middle East. Since receiving FDA approval in 2005, the Omnipod System has been adopted by approximately 425,000 insulin-dependent diabetics worldwide, reflecting the company's commitment to enhancing diabetes management.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

NeoGuide Systems Inc. develops robotic endoscopic technology for natural orifice transluminal endoscopic surgery. Its technology is used in colonoscopy application to provide access to abdominal and thoracic cavities. The company was founded in 2000 and is based in San Jose, California.

Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

Insulet Corporation is a medical device company dedicated to improving the lives of individuals with insulin-dependent diabetes through its innovative Omnipod System. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet develops, manufactures, and markets an insulin delivery system that includes a tubeless, disposable insulin infusion device and a handheld personal diabetes manager. The Omnipod System is designed for ease of use, allowing for automated cannula insertion and smartphone control for dosage management. Insulet primarily sells its products through independent distributors, pharmacy channels, and directly to patients in the United States, Canada, Europe, and the Middle East. Since receiving FDA approval in 2005, the Omnipod System has been adopted by approximately 425,000 insulin-dependent diabetics worldwide, reflecting the company's commitment to enhancing diabetes management.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Insulet Corporation is a medical device company dedicated to improving the lives of individuals with insulin-dependent diabetes through its innovative Omnipod System. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet develops, manufactures, and markets an insulin delivery system that includes a tubeless, disposable insulin infusion device and a handheld personal diabetes manager. The Omnipod System is designed for ease of use, allowing for automated cannula insertion and smartphone control for dosage management. Insulet primarily sells its products through independent distributors, pharmacy channels, and directly to patients in the United States, Canada, Europe, and the Middle East. Since receiving FDA approval in 2005, the Omnipod System has been adopted by approximately 425,000 insulin-dependent diabetics worldwide, reflecting the company's commitment to enhancing diabetes management.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.